-
Product Insights
COBRA – Cristino Castro Solar Power Complex 600 MW – Piaui
Equip yourself with the essential tools needed to make informed and profitable decisions with our COBRA - Cristino Castro Solar Power Complex 600 MW - Piaui report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
COBRA/ Flotation Engy – Morecambe Offshore wind Farm 480 MW – Lincolnshire
Equip yourself with the essential tools needed to make informed and profitable decisions with our COBRA/ Flotation Engy - Morecambe Offshore wind Farm 480 MW - Lincolnshire report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
Grupo Cobra – La Lora Solar Power Complex 200 MW – Castille and Leon
Equip yourself with the essential tools needed to make informed and profitable decisions with our Grupo Cobra - La Lora Solar Power Complex 200 MW - Castille and Leon report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Product Insights
Cobra Energia/ Flotation Energy – Greystones Offshore Wind Farm 1200 MW – Leinster
Equip yourself with the essential tools needed to make informed and profitable decisions with our Cobra Energia/ Flotation Energy - Greystones Offshore Wind Farm 1200 MW - Leinster report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RPI-MN in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RPI-MN in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug Details:RPI-MN (modified cobratoxin) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TAK-186 in Non-Small Cell Lung Cancer Drug Details:TAK-186 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TAK-186 in Colorectal Cancer Drug Details:TAK-186 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Head And Neck Cancer Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TAK-186 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details:TAK-186 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TAK-186 in Solid Tumor Drug Details:TAK-186 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-186 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TAK-186 in Pancreatic Cancer Drug Details:TAK-186 is under development for the treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TAK-280 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug Details:TAK-280 (MVC-280) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Bladder Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TAK-280 in Bladder CancerDrug Details:TAK-280 (MVC-280) is under development for the treatment of unresectable, locally advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TAK-280 in Small-Cell Lung CancerDrug Details:TAK-280 (MVC-280) is under development for the treatment of unresectable, locally...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Head And Neck Cancer Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TAK-280 in Head And Neck Cancer Squamous Cell CarcinomaDrug Details:TAK-280 (MVC-280) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TAK-280 in Solid Tumor Drug Details:TAK-280 (MVC-280) is under development for the treatment of unresectable, locally...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-280 in Metastatic Uveal Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TAK-280 in Metastatic Uveal MelanomaDrug Details:TAK-280 (MVC-280) is under development for the treatment of unresectable, locally...
-
Company Profile
![]()
Molson Coors Beverage Co – Company Profile
Molson Coors Beverage Co (MCBC) produces, develops, and distributes beer and other beverage products. The company markets products under Blue Moon, Hop Valley, Molson Canadian, Cobra, Coors Light, Miller High Life, Steel Reserve, Coors, Lowenbrau, Kamenitza, Molson Ultra, Sharp's, Molson Canadian, Niksicko, Ozujsko, and Belgian White, among others. The company has manufacturing facilities in Canada, the US, Europe, Middle East, and Asia-Pacific. It distributes products through on-premise and off-premise channels that include bars, restaurants, convenience stores, grocery stores, liquor stores,...
Add to Basket -
Product Insights
Coronary Stents – CeloNova BioSciences Inc – COBRA
GlobalData, the industry analysis specialist, has released its latest report: Coronary Stents - CeloNova BioSciences Inc - COBRA. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the...
-
Product Insights
Cobra Field, Ecuador
Each upstream field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide proprietary forecasts of production, capital and operating costs, and other key economic parameters, along-with relevant news, deals and contracts details. This is an on-demand report that will be delivered upon request. The report...
-
Product Insights
Cobra Field, Peru
Each upstream field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide proprietary forecasts of production, capital and operating costs, and other key economic parameters, along-with relevant news, deals and contracts details. This is an on-demand report that will be delivered upon request. The report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.